SPTLC3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL19892760	1.00	3/20
SCHEMBL19892934	1.00	3/20
SCHEMBL19893001	1.00	3/20
SCHEMBL19893173	1.00	3/20
SCHEMBL19893288	1.00	3/20
SCHEMBL19893393	1.00	3/20
SCHEMBL19893317	0.90	3/20
SCHEMBL19893515	0.87	3/20
SCHEMBL34470420	0.86	3/20
SCHEMBL34470506	0.86	3/20
SCHEMBL34470145	0.83	3/20
SCHEMBL34470256	0.83	3/20
SCHEMBL34470382	0.83	3/20
SCHEMBL19892803	0.83	3/20
SCHEMBL19893152	0.83	3/20
SCHEMBL19893231	0.83	3/20
SCHEMBL19892993	0.82	3/20
SCHEMBL19893410	0.82	3/20
SCHEMBL19893453	0.80	3/20
SCHEMBL19893354	0.80	3/20

Clinical trials — most relevant to SPTLC3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis	PHASE4	COMPLETED
Hereditary Sensory Neuropathy Serine Trial	PHASE2	UNKNOWN
Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo	PHASE2	UNKNOWN
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Sphingo-lipotoxicity and Trans-differentiation of Adipose Tissue in Obesity (SFINGOTRANS)	nan	COMPLETED
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.	nan	UNKNOWN
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity.	nan	COMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children	nan	WITHDRAWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN)	nan	COMPLETED
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV	nan	NOT_YET_RECRUITING
Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease	nan	UNKNOWN
Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans	nan	COMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia	nan	UNKNOWN
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)	nan	COMPLETED
Identification of Women With Severe Insulin Resistant Syndromes of Genetic Origin Among Patients With Classic Polycystic Ovary Syndrome (PCOS)	nan	NOT_YET_RECRUITING
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure	nan	COMPLETED
Genomic Dissection of a QTL Affecting the Lipid Profile	nan	WITHDRAWN
Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients With Antiphospholipid Syndrome.	nan	UNKNOWN
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects	nan	UNKNOWN
Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease	nan	COMPLETED
Familial Partial Lipodystrophy Study	nan	COMPLETED
Precision Medicine for Sng/Pain Control	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and Retinopathy in South Wales	nan	RECRUITING
Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects)	nan	UNKNOWN
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis	nan	RECRUITING
Human Liver ORganoids as a Model to Study the Development of Non-Alcoholic SteatOhepatitis (NASH)	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SPTLC3 binder may also engage these)

Protein	Name	Similarity
P97363	—	1.000	P97363 →
Q3B7D2	—	1.000	Q3B7D2 →
O54694	—	0.998	O54694 →
SPTLC2	Serine palmitoyltransferase 2	0.998	landscape →
Q20375	—	0.997	Q20375 →
Q8RYL1	—	0.996	Q8RYL1 →
Q9XVI6	—	0.996	Q9XVI6 →
Q9M304	—	0.995	Q9M304 →
Q8RYL0	—	0.994	Q8RYL0 →
Q5JK39	—	0.993	Q5JK39 →
Q2R3K3	—	0.993	Q2R3K3 →
Q8BG54	—	0.993	Q8BG54 →
Q9LSZ9	—	0.992	Q9LSZ9 →
Q54EX5	—	0.991	Q54EX5 →
P48241	—	0.990	P48241 →
P40970	—	0.990	P40970 →
Q9V7Y2	—	0.988	Q9V7Y2 →
Q8R0X7	—	0.987	Q8R0X7 →
Q05567	—	0.985	Q05567 →
Q52RG7	—	0.984	Q52RG7 →
Q8CHN6	—	0.984	Q8CHN6 →
Q09925	—	0.983	Q09925 →
Q54RV9	—	0.982	Q54RV9 →
SGPL1	Sphingosine-1-phosphate lyase 1	0.982	landscape →
A7SCH8	—	0.982	A7SCH8 →
Q9Y194	—	0.981	Q9Y194 →
Q9C509	—	0.981	Q9C509 →
Q9SR86	—	0.981	Q9SR86 →
Q84P52	—	0.980	Q84P52 →
Q9M0G4	—	0.980	Q9M0G4 →